Discover the price reduction of ENFINIA™ DNA products by 25%, improving access to high-quality DNA for researchers.

Imunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN-101 DNA plasmid vaccine. The investigational vaccine, based on the company ...

Price drop reflects efficiency gains from Co.’s cell-free cloning tech & new facility, where automation & ML have increased ...

A scaleable method for the liquid-phase separation of plasmid DNA from RNA. In the course of experiments on the potential of nucleic acid compaction for enhancement of chromatographic adsorption ...

WuXi Biologics has launched the E coli expression system, EffiX, designed to enhance the production of recombinant proteins ...

coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the ...

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...

Here we show that a heterologous prime-boost vaccination regime of DNA either intramuscularly or epidermally, followed by intradermal recombinant modified vaccinia virus Ankara (MVA), induces high ...

Immunizing the host with a piece of viral DNA rather than an antigenic protein fragment of the virus, helps to stimulate the generation of cell-mediated immunity (Fig. 2). DNA vaccines contain the ...

"As the first-ever plasmid DNA vaccine for human use, ZyCoV-D has proven its safety and efficacy profile in our fight against COVID-19," said the company's managing director Dr Sharvil Patel.